Cencora
VC Fund
Valley Forge, United States
Cencora is a VC fund in Valley Forge focused on Health Care and Medical. Cencora, a company building on the legacy of AmerisourceBergen, is a global pharmaceutical solutions organization centered on improving the lives of people and animals around the world. We connect our pharmaceutical partners, providers, and patients to ensure that anyone can get the therapies they need, where and when they need them. We also helpour partners bring their innovations to patients more efficiently to accelerate positive outcomes.Becoming Cencora has allowed us to combine all the companies and services of AmerisourceBergen. Now, as a unified and internationally inclusive brand, we’re continuing to invest in and focus on our core pharmaceutical distribution business, while also growing our platform of pharma and biopharma services to support pharmaceutical innovation and access. Our 46,000+ worldwide team members are shaping the future of healthcare through the power our purpose: We are united in our responsibility to create healthier futures.AmerisourceBergen, now Cencora, is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500 with more than $230 billion in annual revenue.Headquartered in Valley Forge, Pennsylvania, AmerisourceBergen has locations around the world. It handles about 20% of all of the pharmaceuticals sold and distributed throughout the U.S.They strive to take costs out of the healthcare system by using their scale and efficient operations to drive value for their customers. In addition to delivering pharmaceuticals on a just-in-time basis to tens of thousands of healthcare providers every day, they provide business support and consulting services to help their customers focus on their key strength—caring for patients.AmerisourceBergen is committed to the safety and security of the nation’s pharmaceutical supply chain. They purchase all branded and generic pharmaceuticals only directly from the product’s manufacturer, except in the rare instance that they are required to do otherwise either by the manufacturer or a government agency.
- Total investments:
- 7
- Last investment:
- Lead investor:
- 86%
Last updated:
For AI agents: llms.txt
Industries Cencora invests in
Stages Cencora invests in
Countries Cencora invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Larry Marsh
|
|||
Carl Koeneman
|
|||
Christine Lamm
|
|||
Gina K. Clark
|
|||
Jeffrey L. Vacirca
|
Investment Focus
Industry
- Health Care 3 (43%)
- Medical 2 (29%)
- SaaS 1 (14%)
- Hospital 1 (14%)
- Oncology 1 (14%)
Stage
- Series A 1 (14%)
- Series C 1 (14%)
- Funding Round 1 (14%)
- Corporate Round 1 (14%)
- Secondary Market 1 (14%)
Country
- United States 4 (57%)
- United Kingdom 1 (14%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Larry Marsh
Senior Vice President and Chief Strategy Officer
|
Senior Vice President and Chief Strategy Officer | Total investments: 2 | Find email | |
|
Carl Koeneman
Vice President
|
Vice President | Total investments: 0 | Find email | |
|
Christine Lamm
Manager of Continuous Process Improvement
|
Manager of Continuous Process Improvement | Total investments: 0 | Find email | |
|
Gina K. Clark
Executive Vice President and Chief Communications & Administration Officer
|
Executive Vice President and Chief Communications & Administration Officer | Total investments: 0 | Find email | |
|
Jeffrey L. Vacirca
Medical Director - Integrated Oncology Network
|
Medical Director - Integrated Oncology Network | Total investments: 1 | Find email | |
| See all 13 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Sempre Health
|
Sempre Health is bringing dynamic pricing to healthcare. This allows patients to afford care for longer, which directly improves clinical outcomes / quality measures while reducing utilization / cost.Patients receive texts like, “If you fill your prescription today, you’ll pay $10. If you wait until next week, this could go back up to$30.”We parse millions of prescription records to identify unique patient behaviors. We use this data to predict and seamlessly deliver the right price for the right patient to every pharmacy in the country. At the same time, we’re generating the first ever real-world dataset on patient price sensitivities and cost behaviors. | $20M / Sep 13, 2023 | |
|
Sempre Health
|
Sempre Health is bringing dynamic pricing to healthcare. This allows patients to afford care for longer, which directly improves clinical outcomes / quality measures while reducing utilization / cost.Patients receive texts like, “If you fill your prescription today, you’ll pay $10. If you wait until next week, this could go back up to$30.”We parse millions of prescription records to identify unique patient behaviors. We use this data to predict and seamlessly deliver the right price for the right patient to every pharmacy in the country. At the same time, we’re generating the first ever real-world dataset on patient price sensitivities and cost behaviors. | $20M / Series C / Sep 13, 2023 | |
SteadyMD
|
SteadyMD is a technology company and healthcare provider that delivers high-quality telehealth experiences for consumers, employers, digital health companies, and clinicians.For consumers and employers, the company offers online Primary Care, Functional Medicine, and Pediatric Care.For digital health companies, the company provides an on-demandphysician workforce, medical operations, legal and regulatory guidance, and customized technology.For clinicians, the company offers a variety of telehealth opportunities, from online urgent care to online concierge medicine.The company is licensed, operating, and serving patients in all 50 U.S. states. | Venture - Series Unknown / May 04, 2023 | |
OneOncology
|
OneOncology is a partnership of oncologists and industry leading experts driving the future of community-based cancer care in the United States.They are more than just a network. They are a partnership of independent community oncologists working together as one to deliver comprehensive cancer care with compassion to our patients and theirfamilies, close to home.They empower oncologists to learn from their peers and leverage their collective experience to address the pressures facing community oncology today and to innovate for the future of cancer care delivery. | Secondary Market / Apr 20, 2023 | |
WhizAI
|
WhizAI is the first and only AI-powered analytics platform purpose-built for life sciences and healthcare. It puts insights directly into the hands of business users empowering decision-makers to drive more informed and faster business decisions at lower cost. With its deep understanding of the life sciences and healthcare domains and user intent,the platform delivers insights without the delays of traditional BI dashboards. Fast, easy, and scalable, WhizAI is transforming analytics with artificial intelligence optimized for life sciences and healthcare making WhizAI the trusted partner of choice at top global companies.Simply ask a question about sales, market access, patient services, or clinical trials -- and WhizAI answers it instantly. WhizAI's conversational interface allows users to simply talk to the enterprise data giving them complete autonomy to drill into every level of detail along with real-time updates. WhizAI’s advanced machine learning algorithms scan entire data sets to deliver proactive alerts and automatically surface anomalies, easily pinpointing stagnating sales, market share changes, patient drop-offs and much more.WhizAI enjoys nearly 100% adoption by business users, contributes to a 60% reduction in calls to IT and a 50% reduction in operational overhead within the first few months of implementation. | $6M / Series A / Oct 25, 2022 | |
|
WhizAI
|
WhizAI is the first and only AI-powered analytics platform purpose-built for life sciences and healthcare. It puts insights directly into the hands of business users empowering decision-makers to drive more informed and faster business decisions at lower cost. With its deep understanding of the life sciences and healthcare domains and user intent,the platform delivers insights without the delays of traditional BI dashboards. Fast, easy, and scalable, WhizAI is transforming analytics with artificial intelligence optimized for life sciences and healthcare making WhizAI the trusted partner of choice at top global companies.Simply ask a question about sales, market access, patient services, or clinical trials -- and WhizAI answers it instantly. WhizAI's conversational interface allows users to simply talk to the enterprise data giving them complete autonomy to drill into every level of detail along with real-time updates. WhizAI’s advanced machine learning algorithms scan entire data sets to deliver proactive alerts and automatically surface anomalies, easily pinpointing stagnating sales, market share changes, patient drop-offs and much more.WhizAI enjoys nearly 100% adoption by business users, contributes to a 60% reduction in calls to IT and a 50% reduction in operational overhead within the first few months of implementation. | $8M / Series A / Dec 14, 2021 | |
TrakCel
|
TrakCel's proven technology integrates and orchestrates every aspect of Autologous and Allogeneic supply chains in a scalable, compliant and validated technology platform. | Corporate Round / Mar 03, 2021 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Cencora invest in?
Cencora invests primarily in Health Care, Medical and SaaS startups, most often at Series A and Series C stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Cencora?
Public channels for Cencora include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Cencora?
The team at Cencora includes Larry Marsh (Senior Vice President and Chief Strategy Officer), Carl Koeneman (Vice President) and Christine Lamm (Manager of Continuous Process Improvement), among 13 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
